Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012.

Akmatov, Manas K; Stumme, Melanie; Pessler, Frank

dc.contributor.author	Akmatov, Manas K
dc.contributor.author	Stumme, Melanie
dc.contributor.author	Pessler, Frank
dc.date.accessioned	2016-08-30T15:08:52Z
dc.date.available	2016-08-30T15:08:52Z
dc.date.issued	2016-08-30
dc.identifier.citation	Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012., 34 (3):548-53 Clin. Exp. Rheumatol.	en
dc.identifier.issn	0392-856X
dc.identifier.pmid	27156925
dc.identifier.uri	http://hdl.handle.net/10033/619049
dc.description.abstract	Methotrexate (MTX) is used at low doses to treat rheumatologic disorders in the paediatric age group. Toxicity is observed despite the low doses used. Even though recommendations for monitoring of early signs of toxicity exist in many countries, real-life practice may vary. We therefore assessed current practice in Germany, Switzerland and Austria.
dc.language.iso	en	en
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/4.0/	*
dc.subject.mesh	Adolescent	en
dc.subject.mesh	Antirheumatic Agents	en
dc.subject.mesh	Arthritis, Juvenile	en
dc.subject.mesh	Austria	en
dc.subject.mesh	Child	en
dc.subject.mesh	Child, Preschool	en
dc.subject.mesh	Cross-Sectional Studies	en
dc.subject.mesh	Drug Monitoring	en
dc.subject.mesh	Drug-Related Side Effects and Adverse Reactions	en
dc.subject.mesh	Female	en
dc.subject.mesh	Germany	en
dc.subject.mesh	Humans	en
dc.subject.mesh	Male	en
dc.subject.mesh	Medication Therapy Management	en
dc.subject.mesh	Methotrexate	en
dc.subject.mesh	Switzerland	en
dc.subject.mesh	Young Adult	en
dc.title	Real-life practice of methotrexate toxicity monitoring in juvenile idiopathic arthritis in Germany, Switzerland and Austria: results of a cross-sectional assessment conducted in 2012.	en
dc.type	Article	en
dc.contributor.department	TWINCORE Centre for Experimental and Clinical Infection Research Feodor-Lynen-Str. 7 30625 Hannover, Germany.	en
dc.identifier.journal	Clinical and experimental rheumatology	en
refterms.dateFOA	2017-02-01T00:00:00Z
html.description.abstract	Methotrexate (MTX) is used at low doses to treat rheumatologic disorders in the paediatric age group. Toxicity is observed despite the low doses used. Even though recommendations for monitoring of early signs of toxicity exist in many countries, real-life practice may vary. We therefore assessed current practice in Germany, Switzerland and Austria.